The widespread adoption of GLP-1 receptor agonists is reshaping revenue expectations across the global pharmaceutical sector. Clinical trials demonstrating cardiovascular and renal benefits have expanded target patient populations beyond primary metabolic indications.
Supply Chain and Manufacturing Constraints
Manufacturing capacity remains the primary constraint on market expansion. Major drugmakers are committing billions in capital expenditure to construct dedicated fill-finish production facilities to satisfy sustained global demand.